Management of Breakthrough Psychotic Symptoms

Immediate Management and Monitoring

• Insomnia in patients with breakthrough psychotic symptoms is likely multifactorial, including inadequate antipsychotic coverage, possible fluoxetine activation effects, or primary sleep disorder, and first-line treatment is cognitive behavioral therapy for insomnia (CBT-I), but short-term pharmacologic options like zolpidem 5-10 mg at bedtime can reduce sleep onset latency by 15-18 minutes and increase total sleep time by 23-48 minutes, according to the American College of Physicians, with a moderate strength of evidence 1, 2
• Short-term pharmacologic options for insomnia in patients with breakthrough psychotic symptoms include zolpidem 5-10 mg at bedtime, which reduces sleep onset latency by 15-18 minutes and increases total sleep time by 23-48 minutes, and avoiding benzodiazepines due to risk of dependence and cognitive impairment, as recommended by the American College of Physicians, with a high strength of evidence 1, 2
• Avoiding antihistamines like diphenhydramine for insomnia in patients with breakthrough psychotic symptoms is recommended due to their potential to worsen delirium and have anticholinergic effects, according to the European Society for Medical Oncology, with a low strength of evidence 3
• Assessing sleep quality using subjective sleep onset latency, total sleep time, and number of awakenings is important for monitoring patients with breakthrough psychotic symptoms, as recommended by the American College of Physicians, with a moderate strength of evidence 1, 2
• Avoiding polypharmacy with multiple sedating agents for insomnia in patients with breakthrough psychotic symptoms is recommended, and using one agent short-term while addressing underlying psychosis is advised, according to the American College of Physicians and the European Society for Medical Oncology, with a high strength of evidence 1, 3